NasdaqGM:BSTC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally.


Snowflake Analysis

Flawless balance sheet with proven track record.

Share Price & News

How has BioSpecifics Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BSTC has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

6.7%

BSTC

3.1%

US Biotechs

4.0%

US Market


1 Year Return

3.7%

BSTC

24.2%

US Biotechs

5.0%

US Market

Return vs Industry: BSTC underperformed the US Biotechs industry which returned 22.8% over the past year.

Return vs Market: BSTC underperformed the US Market which returned 4.8% over the past year.


Shareholder returns

BSTCIndustryMarket
7 Day6.7%3.1%4.0%
30 Day5.7%7.0%0.9%
90 Day18.7%31.2%29.5%
1 Year3.7%3.7%25.5%24.2%7.2%5.0%
3 Year20.7%20.7%32.8%28.4%36.2%27.3%
5 Year22.5%22.5%0.04%-5.7%65.4%47.0%

Price Volatility Vs. Market

How volatile is BioSpecifics Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioSpecifics Technologies undervalued compared to its fair value and its price relative to the market?

18.64x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: BSTC ($62.42) is trading above our estimate of fair value ($47.23)

Significantly Below Fair Value: BSTC is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BSTC is good value based on its PE Ratio (18.6x) compared to the Biotechs industry average (19.5x).

PE vs Market: BSTC is poor value based on its PE Ratio (18.6x) compared to the US market (16.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BSTC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BSTC is good value based on its PB Ratio (3.5x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is BioSpecifics Technologies forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

31.1%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if BSTC's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if BSTC's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BSTC's revenue (31.1% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: BSTC's revenue (31.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BSTC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has BioSpecifics Technologies performed over the past 5 years?

24.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BSTC has high quality earnings.

Growing Profit Margin: BSTC's current net profit margins (61.8%) are higher than last year (60.3%).


Past Earnings Growth Analysis

Earnings Trend: BSTC's earnings have grown significantly by 24.6% per year over the past 5 years.

Accelerating Growth: BSTC's earnings growth over the past year (19.7%) is below its 5-year average (24.6% per year).

Earnings vs Industry: BSTC earnings growth over the past year (19.7%) exceeded the Biotechs industry -4.5%.


Return on Equity

High ROE: BSTC's Return on Equity (19%) is considered low.


Next Steps

Financial Health

How is BioSpecifics Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: BSTC's short term assets ($122.9M) exceed its short term liabilities ($3.3M).

Long Term Liabilities: BSTC's short term assets ($122.9M) exceed its long term liabilities ($631.3K).


Debt to Equity History and Analysis

Debt Level: BSTC is debt free.

Reducing Debt: BSTC has not had any debt for past 5 years.

Debt Coverage: BSTC has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: BSTC has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is BioSpecifics Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BSTC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BSTC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BSTC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BSTC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BSTC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.5yrs

Average management tenure


CEO

Joe Truitt (55yo)

0.25

Tenure

Mr. Joseph Truitt, also known as Joe, has been Chairman of the Board at Larimar Therapeutics, Inc., since May 28 2020. He serves as Chief Executive Officer at BioSpecifics Technologies Corp. since May 7, 2 ...


Leadership Team

NamePositionTenureCompensationOwnership
Ronald Law
Senior Vice President of Business Development1.67yrsUS$487.38k0.17% $780.2k
Joseph Truitt
CEO & Director0.25yrno datano data
Patrick Hutchison
Chief Financial Officer0.50yrno datano data
Carl Valenstein
Corporate Secretaryno datano datano data

0.5yrs

Average Tenure

61yo

Average Age

Experienced Management: BSTC's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Joseph Truitt
CEO & Director0.25yrno datano data
Michael Sherman
Independent Director0.25yrno datano data
Paul Gitman
Independent Director30.5yrsUS$202.51k0.20% $936.3k
Michael Schamroth
Independent Director16.17yrsUS$202.51k1.58% $7.2m
Jennifer Chao
Independent Chairman of the Board0.75yrUS$217.51k0.026% $119.8k
Corey Fishman
Independent Director0.25yrno datano data
Toby Wegman
Director13.08yrsUS$156.01k0.026% $118.0k
Mark Wegman
Director13.08yrsUS$187.51k0.91% $4.2m

6.9yrs

Average Tenure

62.5yo

Average Age

Experienced Board: BSTC's board of directors are considered experienced (6.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

BioSpecifics Technologies Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioSpecifics Technologies Corp.
  • Ticker: BSTC
  • Exchange: NasdaqGM
  • Founded: 1957
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$458.472m
  • Shares outstanding: 7.34m
  • Website: https://www.biospecifics.com

Number of Employees


Location

  • BioSpecifics Technologies Corp.
  • Delaware Corporate Center II
  • Suite 200
  • Wilmington
  • Delaware
  • 19803
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BSTCNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDNov 1991
1B3BST (Boerse-Stuttgart)YesCommon StockDEEURNov 1991

Biography

BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren’s contracture and Peyronie’s disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/04 00:27
End of Day Share Price2020/07/02 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.